We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immune Response to Alzheimer's Protein Improves with Age

By Biotechdaily staff writers
Posted on 12 Aug 2003
Researchers seeking to develop a vaccine to prevent Alzheimer's disease have found that some elderly individuals, as well as those with the disease, have elevated levels of T-cells reactive towards Abeta, the amyloid b protein that accumulates and injures the brain.

A vaccine basted on Abeta has been shown to be effective in animals, but clinical trials in humans were terminated when some of the test subjects developed meningoencephalitis. More...


Investigators from Harvard Medical School (Boston, MA, USA) reported in the August 1, 2003, issue of the Journal of Clinical Investigation that they had measured cellular immune responses to Abeta in middle-aged and elderly healthy subjects and in patients with Alzheimer's disease. They found that a significantly higher proportion of healthy elderly subjects and patients with Alzheimer's disease had strong Abeta-reactive T-cell responses than occurred in middle-aged adults. The immunodominant Abeta epitopes in humans resided in amino acids 16–33.

The authors concluded by saying, "The occurrence of intrinsic T-cell reactivity to the self-antigen Abeta in humans has implications for the design of Abeta vaccines, may itself be linked to Alzheimer's disease susceptibility and course, and appears to be associated with the aging process.”




Related Links:
Harvard University Medical School

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Steam Sterilizer
Hi Vac II Line
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.